ArticleFrontiers in microbiology2020
The Multi-Fungicide Resistance Status of
Article in Frontiers in microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 76 citations in OpenAlex.
- A review on fungal pathogens in the One Health framework: connecting plant, animal, and human health.Archives of microbiology · 2026Review
- AMR in wild animals and plants: global trends and future priorities in wildlife-associated antimicrobial resistance research.npj antimicrobials and resistance · 2026Article
- Addressing the dual-use of antifungals and fungal antimicrobial resistance (fAMR) through a One Health approach.npj antimicrobials and resistance · 2026Review
- Epimutations driven by RNAi or heterochromatin evoke transient antimicrobial drug resistance in pathogenic Mucor fungi.PLoS biology · 2026Article
- A One Health Perspective onJournal of fungi (Basel, Switzerland) · 2026Article
- Unravelling soil fungal communities in dumpsites in Kabale, Western Uganda using culturomics.Frontiers in fungal biology · 2026Article
- Evidence that G-quadruplexes form in pathogenic fungi and represent promising antifungal targets.EMBO molecular medicine · 2025Article
- Epimutations driven by RNAi or heterochromatin evoke transient antimicrobial drug resistance in fungi.bioRxiv : the preprint server for biology · 2025Article
- Evolution of antifungal resistance in the environment.Nature microbiology · 2025Review
- Article
- Review
- Moving beyond multi-triazole to multi-fungicide resistance: Broader selection of drug resistance in the human fungal pathogen Aspergillus fumigatus.PLoS pathogens · 2025Article
- Land use drives drug resistance in an airborne human fungal pathogen.The ISME journal · 2025Article
- High prevalence of azole resistance among environmentalFrontiers in microbiology · 2025Article
- Comprehensive analysis of the mechanisms conferring resistance to phenamacril in theFrontiers in cellular and infection microbiology · 2025Review
- RNAi-Based Approaches to Control Mycotoxin Producers: Challenges and Perspectives.Journal of fungi (Basel, Switzerland) · 2024Review
- Environmental Hot Spots and Resistance-Associated Application Practices for Azole-Resistant Aspergillus fumigatus, Denmark, 2020-2023.Emerging infectious diseases · 2024Article
- Catching some air: a method to spatially quantify aerial triazole resistance inApplied and environmental microbiology · 2024Article
- Detection of pan-azole resistant Aspergillus fumigatus in horticulture and a composting facility in Belgium.Medical mycology · 2024Article
- Azole Resistance in Veterinary Clinical Aspergillus fumigatus Isolates in the Netherlands.Mycopathologia · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The evolution and spread of pan-azole resistance alleles in clinical and environmental isolates of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.